DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar Limited
DSS, Inc. announced that Zoar Limited has filed a Form F-4 registration statement with the SEC related to the proposed business combination with Impact Biomedical Inc., in which DSS is a significant stockholder. This filing marks an important procedural milestone but is still subject to SEC review and other approvals before completion.